New injection shows promise for shedding pounds in early trial
NCT ID NCT07114419
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called efsubaglutide alfa for weight loss in 200 adults who are overweight or obese. Participants receive weekly or biweekly injections for 22 weeks, and researchers measure how much weight they lose. The goal is to see if the drug is safe and effective compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Efsubaglutide alfa (a drug injection for weight loss)
What this could lead to
If successful, this could lead to a new treatment option for weight loss in people with overweight or obesity.
What could go wrong
This is an early Phase 2 trial with only 200 people, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Canopy Clinical Altona North
RECRUITINGNorth Altona, Australia
Contact
-
Canopy Clinical Northern Beaches
RECRUITINGBrookvale, Australia
Contact
-
Canopy Clinical Sutherland Shire
RECRUITINGMiranda, Australia
Contact
-
Canopy Clinical Wollongong
RECRUITINGWollongong, Australia
Contact
-
Fusion Clinical Research
RECRUITINGNorwood, Australia
Contact